<DOC>
	<DOCNO>NCT03005184</DOCNO>
	<brief_summary>This study test hypothesis endogenous bradykinin contributes effect combine angiotensin receptor blocker/neprilysin inhibitor ( LCZ696 Entresto )</brief_summary>
	<brief_title>Mechanism ( ) Underlying Cardiovascular Effects ARB/NEP Inhibition - Aim 2</brief_title>
	<detailed_description>Patients heart failure ( HF ) reduce ejection fraction qualify study undergo three-week run-in period prior angiotensin-converting enzyme ( ACE ) inhibitor angiotensin receptor blocker take discontinue give valsartan 80 mg bid single-blind fashion . After run-in , subject undergo four study period random order . During two study period receive enalapril 10 mg bid two receive sacubitril/valsartan ( LCZ696 ) 200 mg bid seven day . On seventh day period , subject complete study day randomize receive either bradykinin B2 receptor blocker icatibant placebo intravenously . Each study period separate three-week washout subject receive valsartan 80 mg bid .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Enalapril</mesh_term>
	<mesh_term>Enalaprilat</mesh_term>
	<mesh_term>Valsartan</mesh_term>
	<mesh_term>Icatibant</mesh_term>
	<mesh_term>LCZ 696</mesh_term>
	<criteria>1 . Stable patient reduce EF 1 . EF le equal 40 % ( confirm echocardiogram within last six month ) , 2. history symptom New York Heart Association class I , II III HF 3. stable clinical symptom include hospitalization last six month 4. treatment stable dose ACEi ARB beta blocker ( unless contraindicate tolerate ) least four week 5. treatment stable dose MR antagonist least four week unless possible due renal function serum potassium . 2 . For female subject , follow condition must meet : 1. postmenopausal status least one year , 2. status postsurgical sterilization 1 . History hypersensitivity allergy study drug , drug similar chemical class , ACEi , ARBs , NEPi , well know suspect contraindication study drug 2 . History angioedema 3 . History pancreatitis know pancreatic lesion 4 . History decompensated HF within last six month ( exacerbation chronic HF manifest sign symptom require intravenous therapy hospitalization ) 5 . History heart transplant transplant list leave ventricular assistance device 6 . Symptomatic hypotension and/or SBP &lt; 100 mmHg screen &lt; 90 mmHg study 7 . Serum potassium &gt; 5.2 mmol/L screen &gt; 5.4 mmol/L study 8 . Acute coronary syndrome , cardiac , carotid , major cardiovascular surgery , percutaneous coronary intervention , carotid angioplasty within six month prior screen 9 . Coronary carotid artery disease likely require surgical percutaneous intervention within six month screen 10 . History serious neurologic disease cerebral hemorrhage , stroke , seizure , transient ischemic attack within six month 11 . History ventricular arrhythmia syncopal episodes 12 . Symptomatic bradycardia second thirddegree atrioventricular block without pacemaker 13 . Presence hemodynamically significant mitral and/or aortic valve disease , except mitral regurgitation secondary LV dilatation 14 . Presence hemodynamically significant obstructive lesion leave ventricular outflow tract , include aortic subaortic stenosis 15 . Type 1 diabetes 16 . Poorly control type 2 diabetes mellitus ( T2DM ) , define HgbA1c &gt; 9 % 17 . Hematocrit &lt; 35 % 18 . Impaired renal function ( eGFR &lt; 30mL/min/1.73 m2 ) determine fourvariable Modification Diet Renal Disease ( MDRD ) equation , serum creatinine ( Scr ) express mg/dL age year : eGFR ( mL/min/1.73m2 ) =175 • Scr1.154 • age0.203 • ( 1.212 Black ) • ( 0.742 female ) 19 . Use hormonereplacement therapy 20 . Breast feeding pregnancy 21 . History presence immunological hematological disorder 22 . History malignancy nonmelanoma skin cancer 23 . Diagnosis asthma require use inhale beta agonist week 24 . Clinically significant gastrointestinal impairment could interfere drug absorption 25 . Impaired hepatic function [ aspartate amino transaminase ( AST ) and/or alanine amino transaminase ( ALT ) &gt; 3.0 x upper limit normal range ] 26 . Any underlying acute disease require regular medication could possibly pose threat subject make implementation protocol interpretation study result difficult , arthritis treat nonsteroidal antiinflammatory drug 27 . Treatment chronic systemic glucocorticoid therapy within last year 28 . Treatment lithium salt 29 . History alcohol drug abuse 30 . Treatment investigational drug one month precede study 31 . Mental condition render subject unable understand nature , scope , possible consequence study 32 . Inability comply protocol , e.g. , uncooperative attitude , inability return followup visit , unlikelihood completing study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>